Business
Geron Announces Appointment of New Members to its Board of Directors
Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies FOSTER
About this update from Geron Corporation
[{"type":"text","content":"Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies\nFOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Patricia S. Andrews and Constantine Chinoporos to its Board of Directors. “We are pleased to welcome Constantine and Pat to the Board, as they bring deep operational expertise cultivated over decades of biopharmaceutical industry leadership, particularly with commercial-stage organizations,” said Elizabeth O’Farrell, Chair of the Board. “Their invaluable insights will be instrumental as we execute on our strategic priorities and drive commercial growth for RYTELO®.” “I am honored to be joining the Board at such a transformational time for Geron,” said Ms. Andrews. “RYTELO is a differentiated treatment option for lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) and has the potential to make a positive difference for people living with this cancer. I look forward to helping the Geron team execute on its refocused commercial strategy for RYTELO and deliver long-term growth.” “With a capable leadership team in place, a focused commercial strategy and strong financial discipline, Geron is well positioned to deliver RYTELO to eligible LR-MDS patients and create long-term value,” said Mr. Chinoporos. “I look forward to supporting the team as we work toward building Geron into a leading, sustainable hematology company.” Ms. Andrews currently serves as a member of the Board of Directors (BOD) of Glenmark Pharmaceuticals Limited, and as a director of its wholly-owned subsidiary, Ichnos Glenmark Innovation (IGI), positions she has held since August 2025. Since 2024, she has also served as a member of the BOD of Oncolytics Biotech Inc. Previously, she served as a member of the BOD and the Audit Committee of GlycoMimetics, Inc., from 2017 until its merger with Crescent Biopharma in 2025. Ms. Andrews served as Chief Executive Officer (CEO) of Sumitomo Pharma Oncology, Inc. (formerly Boston Biomedical, Inc.), and as an Executive Officer of its parent company, Sumitomo Pharma Co., Ltd., from 2017 to 2023. Ms. Andrews was also the Global Head of Oncology for S...